

Product datasheet for **TL309526V**

Heparin Cofactor II (SERPIND1) Human shRNA Lentiviral Particle (Locus ID 3053)

Product data:

Product Type:	shRNA Lentiviral Particles
Product Name:	Heparin Cofactor II (SERPIND1) Human shRNA Lentiviral Particle (Locus ID 3053)
Locus ID:	3053
Synonyms:	D22S673; HC2; HCF2; HCII; HLS2; LS2; THPH10
Vector:	pGFP-C-shLenti (TR30023)
Format:	Lentiviral particles
Components:	SERPIND1 - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble control), 0.5 ml each, >10 ⁷ TU/ml.
RefSeq:	NM_000185 , NM_000185.1 , NM_000185.2 , NM_000185.3 , BC035028 , BC035028.2 , NM_000185.4
UniProt ID:	P05546
Summary:	This gene belongs to the serpin gene superfamily. Serpins play roles in many processes including inflammation, blood clotting, and cancer metastasis. Members of this family have highly conserved secondary structures with a reactive center loop that interacts with the protease active site to inhibit protease activity. This gene encodes a plasma serine protease that functions as a thrombin and chymotrypsin inhibitor. The protein is activated by heparin, dermatan sulfate, and glycosaminoglycans. Allelic variations in this gene are associated with heparin cofactor II deficiency. [provided by RefSeq, Jul 2015]
shRNA Design:	These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact techsupport@origene.com . If you need a special design or shRNA sequence, please utilize our custom shRNA service .



[View online »](#)

**Performance
Guaranteed:**

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).